2023 World Conference on Lung Cancer (Posters)-EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review

EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review - PDF(Abstract)

Back to course

Pdf Summary

This abstract is from a presentation at the World Conference on Lung Cancer in 2023. The presentation focuses on the incidence and mortality of heart failure (HF) in patients with non-small cell lung cancer (NSCLC) who are treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). Cancer and cardiovascular diseases are two leading causes of death, and patients with both conditions experience decreased survival and limited treatment options due to concerns about cardiotoxicity. The aim of the study was to provide an understanding of the risk of HF associated with EGFR TKIs in patients with NSCLC.<br /><br />A targeted literature review was conducted to determine the incidence and mortality of HF in patients with NSCLC treated with EGFR TKIs. The review included electronic and manual searches of relevant publications. The outcomes of interest were the incidence of and mortality due to HF. The review identified 79 articles meeting the eligibility criteria and including a total of 21,985 patients. Among the studies evaluated, HF incidence ranged from 0% to 5.9% in observational studies and from 0% to 8% in clinical trials. HF mortality rates ranged from 0% to 4% in studies evaluating EGFR TKIs.<br /><br />The conclusion of the study is that healthcare providers should monitor patients for signs of cardiotoxicity, specifically related to HF, when prescribing EGFR TKIs. The study suggests the need for standardized definitions of HF-related events and improved monitoring methods for HF in cancer patients.<br /><br />In summary, this presentation provides an overview of the risk of HF associated with EGFR TKIs in patients with NSCLC. It emphasizes the importance of monitoring for cardiotoxicity and calls for further research on HF in cancer patients.

Asset Subtitle

Bilal Khokhar

Meta Tag

Speaker Bilal Khokhar

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

heart failure

non-small cell lung cancer

NSCLC

epidermal growth factor receptor tyrosine kinase inhibitors

EGFR TKIs

incidence

mortality

cardiovascular diseases

observational studies

clinical trials